The goal of this study is to propose the first direct comparison of Ga-68-DOTATATE PET/CT or PET/MR and Ga-68-DOTATOC PET/CT in patients with meningioma.

开始日期2024-05-01

申办/合作机构

Weill Medical College of Cornell University

[+1]

CTR20240013 / Recruiting临床3期

评价镓[68Ga]多特安肽注射液 PET/CT 对神经内分泌瘤（NETs）的诊断效能、药代动力学和安全性及比较镥[177Lu]氧奥曲肽注射液与长效奥曲肽在不可切除或转移性、进展性、分化良好（G1 和 G2）且生长抑素受体阳性的成人胃肠胰神经内分泌瘤患者中的安全性和有效性的诊疗一体化的Ⅲ期临床研究

主要目的：基于相对于真实性标准的受试者水平的灵敏度和特异度，评价镓[68Ga]多特安肽注射液 PET/CT 对 NETs 的诊断效能。次要目的：评价镓[68Ga]多特安肽注射液作为 PET/CT 检查的示踪剂在中国人群中的安全性；评价镓[68Ga]多特安肽注射液作为 PET/CT 检查的示踪剂在中国人群中的药代动力学（PK）及辐射剂量学。

开始日期2024-01-05

申办/合作机构

原子高科股份有限公司

NCT05880394 / Active, not recruiting临床2期IIT

Somatostatin Receptor Imaging Study of Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

This will be a Phase 2 clinical trial to assess somatostatin receptor (SSTR) expression in Stage IV estrogen receptor positive (ER+) breast cancer using Gallium-68 DOTATATE or Copper-64 DOTATATE PET/CT.

开始日期2023-01-10

申办/合作机构

Hoag Memorial Hospital Presbyterian, Inc.

100 项与镓[68Ga]多特安肽相关的临床结果

登录后查看更多信息

100 项与镓[68Ga]多特安肽相关的转化医学

登录后查看更多信息

100 项与镓[68Ga]多特安肽相关的专利（医药）

登录后查看更多信息

176

项与镓[68Ga]多特安肽相关的文献（医药）

2024-03-01·Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

Performance evaluation of Gallium-68 radiopharmaceuticals production using liquid target PETtrace 800 cyclotron

Article

作者: Mahamood, Mazurin ; Halib, Dzulieza ; Adawiyah, Rabiatul ; Ashhar, Zarif ; Aziz, Firdaus ; Mat Ail, Noratikah ; Md Safee, Zaitulhusna ; Jamal Harizan, Muhammad Ali Hazizi ; Ahmad Fadzil, Muhammad Fakhrurazi ; Abd Hamid, Mohd Hamdi Noor ; Ibarhim, Ummi Habibah ; Razali, Nor Idayu ; Said, Mohamad Aminudin ; Alek Amran, Arieffuddin ; Nik Afinde, Nik Muhammad Fitri

Due to increased demand, cyclotron has an expanding role in producing Gallium-68 (⁶⁸Ga) radiopharmaceuticals using solid and liquid targets. Though the liquid target produces lower end-of-bombardment activity compared to the solid target, our study presents the performance of ⁶⁸Ga radiopharmaceuticals production using the liquid target by evaluating the end-of-bombardment activity and the end-of-purification activity of [⁶⁸Ga]GaCl₃. We also present the effect of increasing irradiation time, which significantly improves the end-of-synthesis yield. From the result obtained, the end-of-bombardment activity produced was 4.48 GBq, and the [⁶⁸Ga]GaCl₃ end-of-purification activity produced was 2.51 GBq with below-limit metallic impurities. Increasing the irradiation time showed a significant increase in the end-of-synthesis activity from 1.33 GBq to 1.95 GBq for [⁶⁸Ga]Ga-PSMA-11 and from 1.13 GBq to 1.74 GBq for [⁶⁸Ga]Ga-DOTA-TATE. Based on the improvements made, the liquid target production of ⁶⁸Ga radiopharmaceuticals is feasible and reproducible to accommodate up to 5 patients per production. In addition, this work also discusses the issues encountered, together with the possible corrective and preventative measures.

European journal of nuclear medicine and molecular imaging

Head-to-head comparison between [68Ga]Ga-DOTA-NOC and [18F]DOPA PET/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas

Article

作者: Liao, Zhihong ; He, Qiao ; Zhang, Bing ; Zhang, Zhengkun ; Zhang, Xiangsong ; Zhang, Yuying ; Zhang, Linqi ; Zha, Zhihao ; Long, Yali

PURPOSE:

To compare the detection ability of ⁶⁸Ga-labelled DOTA-l-Nal3-octreotide ([⁶⁸Ga]Ga-DOTA-NOC) and 6-[¹⁸F]fluoro-L-3,4-dihydroxyphenylalanine ([¹⁸F]DOPA) in patients with phaeochromocytomas and paragangliomas (PPGLs) of different origins and gene mutations, such as germline succinate dehydrogenase complex genes (SDHx).

METHODS:

Eighty-five patients with histopathologically confirmed PPGLs who underwent both [⁶⁸Ga]Ga-DOTA-NOC and [¹⁸F]DOPA PET/CT from March 2017 to June 2023 were enrolled in this retrospective study. For comparative analyses, PPGLs were classified as phaeochromocytoma (PCC), sympathetic paraganglioma (sPGL), and head/neck paraganglioma (HNPGL). Detection rates were analyzed on per-patient and per-lesion bases and compared using the Chi-square/Fischer's exact test.

RESULTS:

Among 85 patients with PPGLs (48 males; 43 years ± 17 [SD]), the patient-based detection rates of [⁶⁸Ga]Ga-DOTA-NOC and [¹⁸F]DOPA PET/CT were 87.1% (74/85) and 89.4% (76/85), respectively (p = 0.634), and the lesion-based detection rates were 80.8% (479/593) and 71.2% (422/593), respectively (p < 0.001). Only one patient with a recurrent PCC presented double-negative imaging, while 66 patients exhibited double-positive imaging. The remaining patients were either [⁶⁸Ga]Ga-DOTA-NOC-negative/[¹⁸F]DOPA-positive (n = 10) or [⁶⁸Ga]Ga-DOTA-NOC-positive/[¹⁸F]DOPA-negative (n = 8). In subgroup analyses, [⁶⁸Ga]Ga-DOTA-NOC PET/CT detected significantly more metastases of sPGL (91.1%, 236/259) and SDHx-related PPGL (89.6%, 86/96) than [¹⁸F]DOPA PET/CT (48.6%[126/259] and 50.0%[48/96], respectively; both p < 0.001). However, [¹⁸F]DOPA showed significantly higher detection rates of PCC in both primary/recurrent and metastatic lesions (94.3%[50/53] vs. 62.3%[33/53] and 87.9%[174/198] vs. 69.2%[137/198], respectively; both p < 0.001). Regarding metastases in different organs, [⁶⁸Ga]Ga-DOTA-NOC PET/CT detected more lesions than [¹⁸F]DOPA PET/CT in bone (96.2%[176/183] vs. 66.1%[121/183]; p < 0.001) and lymph nodes (82.0%[73/89] vs. 53.9%[48/89]; p < 0.001) but less lesions in peritoneum (20%[4/20] vs. 100%[20/20]; p < 0.001).

CONCLUSION:

[⁶⁸Ga]Ga-DOTA-NOC and [¹⁸F]DOPA are complementary in diagnosing PPGL under the appropriate clinical setting. [⁶⁸Ga]Ga-DOTA-NOC should be considered as the ideal first-line tracer for detecting metastases of sPGL and SDHx-related tumours, whereas [¹⁸F]DOPA may be the optimal tracer for evaluating non-SDHx-related PCC, especially in detecting primary lesions and monitoring recurrence.

2024-01-01·Hormone research in paediatrics

An Overlooked Manifestation of Hypercortisolism: Cerebral Cortical Atrophy and Challenges in Identifying the Etiology of Hypercortisolism – A Report of 2 Pediatric Cases

作者: Hatun, Sukru ; Guran, Tulay ; Yesiltepe Mutlu, Gul ; Eviz, Elif ; Arduc Akcay, Ayfer ; Erbey, Fatih

Introduction: Endogenous Cushing’s syndrome (CS) is a rare, severe disease that can cause multiple systemic involvements and behavioral problems due to excessive cortisol production. Structural changes can be noted in the brain magnetic resonance imaging (MRI) scans of these cases. Cases: A 9-year-old girl and a 13-year-old boy were admitted with hypercortisolism. In the female patient, altered consciousness was prominent along with cerebral and cerebellar brain atrophy, and findings indicating posterior reversible encephalopathy syndrome were detected in the brain MRI. Although the male patient’s neurological examination was normal, significant cerebral atrophy was seen in the brain MRI. Case 1 was diagnosed as having ectopic ACTH syndrome (EAS) due to a thymic carcinoid tumor. Case 2 underwent a pulmonary lobectomy upon detection of a bronchial lesion in the Ga-68 DOTATATE PET/CT scan while being examined for EAS due to a lack of suppression in the high-dose dexamethasone suppression test. However, hypercortisolism persisted despite the removal of the bronchial lesion, and subsequently, a diagnosis of Cushing’s disease was established following bilateral inferior petrosal sinus sampling. Discussion: Endogenous hypercortisolism may cause brain atrophy of varying severity. The central nervous system findings can be overlooked in children with CS. More comprehensive studies are needed to better understand the behavioral changes caused by the effects on the brain and to evaluate whether these changes are reversible. In addition, identifying the source of hypercortisolism can be difficult due to a lack of experience related to the rarity of the disease in children.

项与镓[68Ga]多特安肽相关的新闻（医药）

2024-06-06

·BioPharmaDive

Germany’s ITM raises $205M as radiopharma field booms

Dive Brief:Radiopharmaceutical drug developer ITM has raised 188 million euros, or about $205 million, to fund its development of the targeted radiation therapies for cancer.Announced by ITM Thursday, the financing is the latest evidence of the substantial investment flowing into the field of radiopharmaceuticals, which are designed to deliver a cancer-killing radioisotope directly into tumors while sparing nearby healthy tissue.ITM, short for Isotope Technologies Munich, has advanced a radiopharmaceutical drug for a type of gastrointestinal cancer into two Phase 3 studies that are estimated to complete this year and in 2027. Uniquely, ITM is also a supplier of radioisotopes, including the commonly used lutetium-177.Dive Insight:Thursdays funding comes almost exactly one year after ITM raised 255 million euros from the same group of investors, a syndicate that includes Temasek, BlackRock and the Qatar Investment Authority.In the 12 months since that June 2023 funding, four of ITMs radiopharma peers have been acquired in deals worth a combined $8.5 billion. Several others have struck research collaborations with large drugmakers like Eli Lilly and Roche. And hundreds of millions of dollars in investment have flown into new startups.Steffen Schuster, the longtime CEO of ITM, hasnt been surprised by the frenzy of activity. Hes expected as much since Novartis acquired the radiopharma company Endocyte five years ago, gaining a prostate cancer treatment it now sells as Pluvicto.We said as soon as Pluvicto is a blockbuster, big pharma will wake up and say, Hey, wait a minute, I missed the train, Schuster said in an interview.Pluvicto sales last year totaled $980 million and Novartis expects theyll eventually reach triple that sum each year. The success of Pluvicto and another radiopharma Novartis sells called Lutathera have helped convince other large companies that the drug class is an essential building block for their oncology pipelines. Bristol Myers spent $4.1 billion to buy RayzeBio; AstraZeneca paid $2 billion for Fusion Pharmaceuticals; and Eli Lilly bought Point Biopharma for $1.4 billion.The whole market has changed completely, Schuster said.The executive declined to comment on whether ITM has had discussions with larger firms, but said that its position supplying isotopes and developing drugs both gives it control and builds value.The bulk of the new funding will go toward ITMs pipeline, which is led by its gastrointestinal cancer drug ITM-11. Other treatments are in much earlier phases of testing, but involve a range of tumor types as well as radioisotopes.ITM-11 is aimed at the same target as Novartis Lutathera and uses the same isotope: lutetium-177. Schuster noted differences in its dosing intervals as well as in some of the treatments components, however.[The goal] is not just taking market share from Novartis, said Schuster. Its creating a larger market. There are so many patients who could get this treatment who dont get treatment.In addition to development, ITM currently manufactures and supplies lutetium-177 as well as an imaging radioisotope known as gallium-68. In January, the company said a new production site in Germany was ready for business and, several months prior, launched a joint venture with Canadian Nuclear Laboratories to produce actinium-225, another radioisotope that drugmakers are using.There are so many synergies between these two parts of the businesses, said Schuster.Along with Temasek, BlackRock and Qatar Investment Authority, investors Athos and Carbyne were involved in ITMs fundraising. Nextech, which participated in the June 2023 funding, was not among the named investors in Thursdays announcement. '

并购放射疗法临床3期

2024-05-21

·BioSpace

Evergreen Theragnostics announces licensing of EVG321 from Medical University of Innsbruck and enters clinical development of Radioligand Therapies in small cell lung cancer

SPRINGFIELD, N.J., May 21, 2024 /PRNewswire/ -- Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced that they have entered into a collaboration and licensing-agreement with the Innsbruck Medical University (MUI), a leading European research institution to advance the development of novel radiopharmaceuticals. The agreement covers the clinical development of EVG321, a novel radioligand therapy (RLT) for small cell lung cancer (SCLC), targeting the cholecystokinin 2 receptor (CCK2R). RLTs have surged into the clinic and represent a rapidly expanding market. By combining the power of medical isotopes and the precision of targeted therapeutics, these types of medicines allow for cell-specific ablation of a tumor target, thereby localizing ionizing radiation to diseased tissues. CCK2R has been shown to be highly expressed in SCLC, and has the potential to facilitate robust, tumor-specific delivery. "We are very pleased to announce this new collaboration with the Medical University of Innsbruck," commented James Cook, CEO of Evergreen Theragnostics. "For several years, the research groups of Univ. Prof. Dr. Irene Virgolini and Priv. Doz. Dr. Elisabeth von Guggenberg in Innsbruck have established themselves as key innovators in the RLT-field, and we are excited to be working with them on one of their lead programs – this was an easy choice to make." He added: "Especially in the realm of small cell lung cancer, novel therapies are urgently needed, and we are confident that EVG321 has the potential to significantly improve outcomes for cancer patients in this indication." Univ. Prof. Dr. Irene Virgolini, Medical University of Innsbruck, said: "Evergreen Discovery is a pioneer in the field of radiopharmaceuticals, and their team is looking back on an impressive record in bringing novel medicines to patients. We are delighted to be collaborating with them. In conjunction with their subject matter expertise and proven ability to translate new radioligand therapies, it is their exceptional sense of urgency to bring novel drugs to patients in need, making them such valuable partners for us." Over the next months, Evergreen intends to begin registration enabling therapeutic and diagnostic clinical trials for Lutetium-177 (177Lu) EVG321 and Gallium-68 (68Ga) EVG321. If successful, EVG321 could offer new hope to patients with small cell lung cancer. About Evergreen Theragnostics, Inc. Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary products. Evergreen is headquartered in Springfield, NJ in a state-of-the-art GMP radiopharmaceutical facility. The company was founded in 2019 by a team that brings a strong track record in theragnostic radiopharmaceutical manufacturing, research, and clinical development. For more information, please visit . About Medical University of Innsbruck Medical University of Innsbruck has approximately 2,200 employees and around 3,400 students and, together with the University of Innsbruck, is the largest educational and research institution in western Austria and the regional university for Tyrol, Vorarlberg, South Tyrol and Liechtenstein. Medical University of Innsbruck is involved in numerous international educational and research programmes and networks. The research focuses on the areas Oncology, Neuroscience, Genetics, Epigenetics and Genomics as well as Infectious Diseases, Immunology & Organ and Tissue Repair. In addition to scientific research, Medical University of Innsbruck is also nationally and internationally very successful in the highly competitive field of research funding. For more information on Medical University of Innsbruck, please visit For further information, please contact: James Cook President & CEO james.cook@evergreentgn.com

引进/卖出

2024-04-16

·PRNewswire

Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services

SPRINGFIELD, N.J., April 16, 2024 /PRNewswire/ -- Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT. The financing advances Evergreen's novel discovery pipeline into clinical trials, supports commercialization of its diagnostic agent, and further expands CDMO capabilities to meet growing client demand. "We have been advancing our discovery pipeline and are excited to take the next step in development," commented James Cook, CEO. "As we continue to work with the FDA on approval of our Ga-68 DOTATOC diagnostic kit, this new funding will enable us to rapidly progress our novel theragnostic pair, EVG-321, into clinical trials. In addition, our CDMO business is continuing to build momentum as we bring on new customers and expand our efforts with existing ones. We appreciate the trust given to us by our existing and new shareholders in advancing our priorities." "We have tracked Evergreen since the company's inception and are excited to partner with James and his team as they bring best- and first-in-class candidates into the clinic, broaden their top-tier radiopharma drug discovery efforts, prepare for commercial launch of their diagnostic product, and further capitalize on the highly specialized expertise required to build and run a radiopharma CDMO," said Patrick Lally, Partner at Petrichor. Stefano Buono, chairman of LIFTT and founder and former CEO of Advanced Accelerator Applications (AAA) noted, "the radioligand therapy industry is advancing rapidly. Our investment in Evergreen Theragnostics deepens our commitment to this exciting area with a company that is well-positioned to succeed." Evergreen has established a lean and experienced team of scientific, medical, commercial, and operational leaders and employees to continue to develop our capabilities. Over the next months, Evergreen will continue to plan for the launch of our diagnostic agent Octevy™, subject to approval by the FDA. Evergreen Discovery also intends to begin registration enabling therapeutic and diagnostic clinical trials for Lutetium-177 (177Lu) EVG-321 and Gallium-68 (68Ga) EVG-321, a novel radiopharmaceutical theragnostic pair, which, if successful, could offer new hope to patients with small cell lung cancer. About Evergreen Theragnostics, Inc. Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary products. Evergreen is headquartered in Springfield, NJ in a state-of-the-art GMP radiopharmaceutical facility. The company was founded in 2019 by a team that brings a strong track record in theragnostic radiopharmaceutical manufacturing and commercialization. For more information, please visit . About Petrichor Petrichor partners with world-class healthcare managers and businesses to provide customized investment structures and support. The Petrichor team has completed over 125 investments representing more than $6 billion in invested capital and has held over 55 board seats. Petrichor maintains a deep in-house understanding of healthcare products and services, including scientific, technical, and commercial expertise. This healthcare expertise, together with a breadth of experience investing across sectors, geographies, and capital structures, provides a unique combination to help build successful companies. For more information on Petrichor, please see or contact the firm at [email protected]. About LIFTT LIFTT is an Italian Venture Capital operating in every industry with a focus on deep-tech. To date it has raised €103,7M and completed 50 investments in innovative start-ups. While generating value for its shareholders, LIFTT supports the creation of businesses, development, employment, and economic growth, through the implementation of an ethical and transparent governance model. To learn more, please visit For further information, please contact: James Cook President & CEO [email protected] SOURCE Evergreen Theragnostics, Inc.

100 项与镓[68Ga]多特安肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V09	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
神经内分泌肿瘤	美国	Advanced Accelerator Applications USA, Inc.	2016-06-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃肠胰神经内分泌肿瘤	临床3期	中国	原子高科股份有限公司	2024-01-05
ER阳性乳腺癌	临床2期	美国	Hoag Memorial Hospital Presbyterian, Inc.	2023-01-10
ER阳性乳腺癌	临床2期	美国	Rayzebio, Inc.初创企业	2023-01-10
转移性乳腺癌	临床2期	美国	Rayzebio, Inc.初创企业	2023-01-10
转移性乳腺癌	临床2期	美国	Hoag Memorial Hospital Presbyterian, Inc.	2023-01-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2024	N/A	神经内分泌肿瘤	-	Cu64-dotatate-PET/CT	鏇淵膚醖憲繭網築窪構(範淵鑰積簾夢夢蓋獵淵) = 廠遞齋製繭夢鬱醖襯鹹淵齋築鏇鏇憲範構製鏇 (淵選鏇獵糧製夢夢鹹齋 ) 更多	-	2024-05-24
ASCO2024	N/A	神经内分泌肿瘤	-	Ga68-dotatate-PET/CT	鏇淵膚醖憲繭網築窪構(範淵鑰積簾夢夢蓋獵淵) = 鑰積範襯繭顧構築製繭淵齋築鏇鏇憲範構製鏇 (淵選鏇獵糧製夢夢鹹齋 ) 更多	-	2024-05-24
ASCO_GI2023	N/A	APUD瘤	424	Ga68-DOTATE (Patients with well-differentiated NETs of GI and pancreatic origin)	構淵網願獵鏇遞餘鹹壓(蓋淵網窪選壓構觸選醖) = 鹹鏇獵齋憲廠網鏇遞廠艱鑰願壓繭鑰築範製襯 (窪範夢觸觸艱鹹糧積壓 ) 更多	-	2023-01-24
ASCO_GI2023	N/A	APUD瘤	424	Ga68-DOTATE (Patients with lung carcinoid)	艱壓蓋餘壓醖糧襯獵憲(鬱鏇願鏇壓築遞淵積選) = 鹽獵繭壓壓顧鑰構顧簾夢選膚窪選選夢鑰膚網 (鑰廠蓋構繭觸窪鏇積夢 )	-	2023-01-24
NCT03549598 (CTgov)	临床4期	心脏结节病	15	13NH3 PET/CT scan+18FDG PET/CT scan+68Ga-DOTATATE PET/CT	糧襯鹹夢醖觸衊鑰願窪(壓廠鹽淵憲襯艱夢淵膚) = 餘壓繭範襯鹹鑰鹽遞鑰鏇願鏇淵鏇築憲窪鬱淵 (淵憲觸壓製願選製願齋, 醖憲觸繭餘壓鏇顧繭鹽 ~ 糧廠顧襯積淵範餘願簾) 更多	-	2020-10-20
NCT02546388 (CTgov)	N/A	心脏结节病	17	Gallium-68 DOTATATE (Gallium-68 DOTATATE)	願選鏇選鹹壓鑰顧夢夢(鏇鏇膚齋鏇遞網鑰願顧) = 醖築鑰願鹽範鏇窪顧鹹製蓋製鑰壓齋餘憲窪範 (膚選觸齋製壓範窪醖鑰, 餘遞顧獵憲鏇衊願觸衊 ~ 鬱繭廠簾廠鹹製遞夢糧) 更多	-	2020-03-25
NCT02546388 (CTgov)	N/A	心脏结节病	17	Indium-111 Pentreotide (Indium-111 Pentreotide (OctreoScan))	願選鏇選鹹壓鑰顧夢夢(鏇鏇膚齋鏇遞網鑰願顧) = 鏇製壓膚窪積繭鏇願憲製蓋製鑰壓齋餘憲窪範 (膚選觸齋製壓範窪醖鑰, 艱齋鹽衊鑰鹽艱艱醖鏇 ~ 構選繭廠壓遞壓繭製艱) 更多	-	2020-03-25
NCT01967537 (CTgov)	临床2期	希佩尔·林道综合征 \| 神经内分泌肿瘤	341	Radio-guided surgery+68Gallium DOTATATE	齋憲製醖襯網積願壓鹹(鑰淵艱願獵廠衊範襯鹹) = 鏇鏇鬱選糧範膚餘簾遞壓壓鬱範鑰鑰繭衊憲淵 (構網憲觸夢鹹簾齋齋網, 遞艱憲獵淵鹽艱構憲繭 ~ 糧窪糧構膚艱獵觸鏇艱) 更多	-	2019-04-02
ASCO_GI2019	N/A	神经内分泌肿瘤	101	Ga-68 Dotatate PET/CT	獵壓簾選遞衊構鏇憲選(齋廠鹹觸鏇膚築膚觸壓) = 選廠顧築膚糧鹽顧網鹹鏇鹽廠範鹹膚鹽糧衊網 (壓夢顧顧遞壓鬱築鑰餘 )	积极	2019-01-29